Skip to content
PubMed This is a summary of 14 peer-reviewed journal articles Updated
Nephrology

Life After Transplant: Parathyroid and Bone Health

At a Glance

After a kidney transplant, parathyroid hormone (PTH) may remain high for months because enlarged glands take time to recover. Regular calcium, phosphorus, and PTH monitoring helps your team identify persistent or tertiary hyperparathyroidism and protect your bones and new kidney.

Receiving a kidney transplant is a major milestone, but for your parathyroid glands, it is often a period of transition rather than an instant “cure” [1]. While a new, functioning kidney restores your body’s ability to activate Vitamin D and clear phosphate, your parathyroid glands may need time to “unlearn” the overactive behavior they developed during your years of kidney disease [2][3].

Understanding Persistent and Tertiary Hyperparathyroidism

In the months following a successful transplant, many patients see their parathyroid hormone (PTH) levels begin to gradually drop [1]. However, if your parathyroid glands grew significantly larger during kidney failure, they may continue to overproduce hormone even though the original trigger is gone [2].

  • Persistent Hyperparathyroidism: It is very common to have elevated PTH for months after a transplant [4]. In many cases, the glands will slowly shrink, and PTH will eventually improve [1].
  • Tertiary Hyperparathyroidism: If the parathyroid glands become “autonomous” and no longer respond to normal bodily feedback, they can drive blood calcium to dangerous levels. This clinical diagnosis, often called tertiary hyperparathyroidism, requires specialized medical evaluation. A subset of recipients develop this condition [4][5]. It is evaluated based on the full clinical picture of severe hypercalcemia and persistently elevated PTH, rather than a strict timeline [6][4].

Why Post-Transplant Monitoring Matters

It is vital to keep monitoring your “bone-mineral markers” (calcium, phosphorus, and PTH) after a transplant.

  1. Graft Health: Observational studies have noted an association between very high post-transplant PTH levels and a higher risk of poor graft outcomes [7]. This does not mean a single high PTH number predicts kidney failure, but it emphasizes why managing your mineral balance remains important to your transplant team.
  2. Early Mineral Swings: In the first few weeks after transplant, it is common to experience hypophosphatemia (low blood phosphorus). This happens partly because the elevated FGF23 and PTH hormones still circulating in your blood force your new kidney to excrete excess phosphate [1]. Your team will monitor this closely and individualize phosphate replacement if needed.
  3. Bone Strength: Even with a new kidney, your bone health remains a priority. Many transplant recipients transition from “high-turnover” bone disease to “low-turnover” bone disease, which can still leave bones fragile [8][9]. The use of corticosteroids (steroid medications) to prevent transplant rejection can also weaken bones [10].

Managing Life with CKD-MBD

Whether you are on dialysis or have received a transplant, managing the long-term effects of SHPT requires a proactive approach.

  • Partner with Your Team: Your care now involves a multidisciplinary team, often including your nephrologist, transplant surgeon, and sometimes an endocrinologist [11]. Do not change your diet, phosphate binders, or supplements without consulting them, as this can affect your new kidney. Focus on Trends: Don’t let a single “out-of-range” lab result cause anxiety. Your team is looking for persistent rises or falls over several months [12].
  • Bone Density Testing: Your doctor may recommend a DEXA scan to measure your bone mineral density. While DEXA results can be complex to interpret in CKD patients, it is one tool (among labs and clinical history) your team uses to assess bone health. A DEXA scan alone does not automatically trigger the use of bone-building medications, as these drugs must be used very cautiously in transplant patients [13][14].
  • Heart Health: Because mineral imbalances can lead to vascular calcification, staying active and managing blood pressure are just as important for your bone-mineral health as they are for your heart [11].

Living with SHPT and CKD-MBD is a long-term journey of balance. By understanding the biology and staying consistent with your monitoring and immunosuppressant medications, you are taking the most important steps to protect your skeleton and your new kidney.

Common questions in this guide

Is it normal for PTH to stay high after a kidney transplant?
Yes, parathyroid hormone can remain elevated for months after a successful transplant because enlarged parathyroid glands may take time to recover. Levels often decline gradually, but persistently high PTH with high blood calcium needs evaluation for tertiary hyperparathyroidism.
Which blood tests are monitored after a kidney transplant?
Your team may follow parathyroid hormone, calcium, and phosphorus, along with other measures of kidney and graft health. Looking at trends over time is usually more useful than reacting to one out-of-range result, and low phosphorus can occur early after transplant.
What is tertiary hyperparathyroidism after kidney transplantation?
Tertiary hyperparathyroidism occurs when the parathyroid glands continue making too much hormone independently after the original kidney-related trigger has improved. Doctors evaluate it using the overall clinical picture, especially persistently high PTH together with severe high blood calcium.
How can a kidney transplant affect bone health?
Bone may remain fragile after transplant because long-term kidney disease can alter bone turnover, and steroid medicines used to prevent rejection can weaken bone. Your team may use blood tests, medical history, and sometimes a DEXA scan to assess bone health.
Should I change my diet or phosphate supplements after a kidney transplant?
Do not change your diet, phosphate binders, or supplements without speaking with your transplant team. Improved kidney function can change your mineral needs, and the right plan depends on your calcium, phosphorus, PTH, kidney function, and medicines.
When might medication or parathyroid surgery be considered?
If PTH remains high after transplant, clinicians first review the laboratory pattern, symptoms, kidney function, and possible medical treatments. Parathyroid surgery may be considered for selected patients with ongoing gland overactivity, particularly when high calcium or other complications persist.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Based on my pre-transplant PTH levels, what is my risk of developing persistent hyperparathyroidism?
  2. 2.Now that I have my transplant, how often will we monitor my calcium and phosphorus to check for persistent gland overactivity?
  3. 3.If my PTH remains high months after surgery, what medications might we use before considering parathyroid surgery?
  4. 4.How do my current immunosuppressants (like steroids) interact with my long-term bone health plan?
  5. 5.How should I adjust my diet now that my kidney function has improved, and should I still be limiting certain minerals?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (14)
  1. 1

    A Prospective Cohort Study of Mineral Metabolism After Kidney Transplantation.

    Wolf M, Weir MR, Kopyt N, et al.

    Transplantation 2016; (100(1)):184-93 doi:10.1097/TP.0000000000000823.

    PMID: 26177089
  2. 2

    Chronic Kidney Disease-Mineral Bone Disease Biomarkers in Kidney Transplant Patients.

    Hasparyk UG, Vigil FMB, Bartolomei VS, et al.

    Current medicinal chemistry 2022; (29(31)):5230-5253 doi:10.2174/0929867329666220318105856.

    PMID: 35306980
  3. 3

    Recent Changes in Chronic Kidney Disease-Mineral and Bone Disorders and Associated Fractures After Kidney Transplantation.

    Perrin P, Kiener C, Javier RM, et al.

    Transplantation 2017; (101(8)):1897-1905 doi:10.1097/TP.0000000000001449.

    PMID: 27547867
  4. 4

    Prevalence and risk factors for tertiary hyperparathyroidism in kidney transplant recipients.

    Sutton W, Chen X, Patel P, et al.

    Surgery 2022; (171(1)):69-76 doi:10.1016/j.surg.2021.03.067.

    PMID: 34266650
  5. 5

    Incidence, risk factors and survival outcomes of post-transplant tertiary hyperparathyroidism in kidney recipients.

    Hanson S, Menendez Lorenzo J, Chukwu CA, et al.

    World journal of transplantation 2026; (16(1)):103656 doi:10.5500/wjt.v16.i1.103656.

    PMID: 41607829
  6. 6

    Surgery for kidney-related hyperparathyroidism: A review.

    Kasmirski JA, Swaminathan N, Roy R, et al.

    American journal of surgery 2026; (254()):116854 doi:10.1016/j.amjsurg.2026.116854.

    PMID: 41691949
  7. 7

    Hyperparathyroidism at 1 year after kidney transplantation is associated with graft loss.

    Crepeau P, Chen X, Udyavar R, et al.

    Surgery 2023; (173(1)):138-145 doi:10.1016/j.surg.2022.07.031.

    PMID: 36244806
  8. 8

    Changes in Bone Histomorphometry after Kidney Transplantation.

    Keronen S, Martola L, Finne P, et al.

    Clinical journal of the American Society of Nephrology : CJASN 2019; (14(6)):894-903 doi:10.2215/CJN.09950818.

    PMID: 31088851
  9. 9

    Patterns of renal osteodystrophy 1 year after kidney transplantation.

    Jørgensen HS, Behets G, Bammens B, et al.

    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2021; (36(11)):2130-2139 doi:10.1093/ndt/gfab239.

    PMID: 34383929
  10. 10

    Natural History of Bone Disease following Kidney Transplantation.

    Jørgensen HS, Behets G, Bammens B, et al.

    Journal of the American Society of Nephrology : JASN 2022; (33(3)):638-652 doi:10.1681/ASN.2021081081.

    PMID: 35046132
  11. 11

    A roadmap to parathyroidectomy for kidney transplant candidates.

    Cianciolo G, Tondolo F, Barbuto S, et al.

    Clinical kidney journal 2022; (15(8)):1459-1474 doi:10.1093/ckj/sfac050.

    PMID: 35892022
  12. 12

    Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD): Current Perspectives.

    Waziri B, Duarte R, Naicker S

    International journal of nephrology and renovascular disease 2019; (12()):263-276 doi:10.2147/IJNRD.S191156.

    PMID: 31920363
  13. 13

    Bone mineral density, bone turnover markers, and incident fractures in de novo kidney transplant recipients.

    Evenepoel P, Claes K, Meijers B, et al.

    Kidney international 2019; (95(6)):1461-1470 doi:10.1016/j.kint.2018.12.024.

    PMID: 30922664
  14. 14

    [Diagnosis and treatment of osteoporosis in patients with chronic kidney disease : Joint guidelines of the Austrian Society for Bone and Mineral Research (ÖGKM), the Austrian Society of Physical and Rehabilitation Medicine (ÖGPMR) and the Austrian Society of Nephrology (ÖGN)].

    Cejka D, Wakolbinger-Habel R, Zitt E, et al.

    Wiener medizinische Wochenschrift (1946) 2023; (173(13-14)):299-318 doi:10.1007/s10354-022-00989-0.

    PMID: 36542221

This page explains persistent secondary or tertiary hyperparathyroidism and bone health after kidney transplant for informational purposes only and does not constitute medical advice. Your transplant and kidney-care teams should interpret your lab results and guide diet, supplements, and treatment.

Get notified when new evidence is published on secondary hyperparathyroidism of renal origin.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.